Scalable Synthesis of CVN424, an Inverse Agonist of the GPR6 Receptor

Mu, CW; Li, XL; Yang, YF; Zhou, YS; Wang, CH; Doyle, KJ; Ye, ND; Mistry, A; Bürli, RW

Bürli, RW (通讯作者),Cerevance Ltd, 418 Cambridge Sci Pk,Milton Rd, Cambridge CB4 0PZ, England.

ORGANIC PROCESS RESEARCH & DEVELOPMENT, 2023; 27 (2): 256

Abstract

CVN424 is a drug candidate, which is being investigated in clinical trials for the treatment of motor fluctuations associated with Parkinson's disease......

Full Text Link